Mirati Therapeutics, Inc. (NASDAQ:MRTX) SVP Jamie Christensen sold 10,814 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $27.00, for a total transaction of $291,978.00. Following the completion of the sale, the senior vice president now directly owns 13,691 shares in the company, valued at $369,657. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Jamie Christensen also recently made the following trade(s):
- On Thursday, January 11th, Jamie Christensen sold 14,725 shares of Mirati Therapeutics stock. The shares were sold at an average price of $22.99, for a total transaction of $338,527.75.
- On Thursday, November 16th, Jamie Christensen sold 10,275 shares of Mirati Therapeutics stock. The shares were sold at an average price of $18.00, for a total transaction of $184,950.00.
- On Thursday, November 2nd, Jamie Christensen sold 7,499 shares of Mirati Therapeutics stock. The shares were sold at an average price of $14.00, for a total transaction of $104,986.00.
Shares of Mirati Therapeutics, Inc. (MRTX) opened at $25.60 on Friday. Mirati Therapeutics, Inc. has a 12 month low of $2.70 and a 12 month high of $27.85. The firm has a market cap of $728.83, a price-to-earnings ratio of -8.23 and a beta of 1.79.
Mirati Therapeutics (NASDAQ:MRTX) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.16. sell-side analysts expect that Mirati Therapeutics, Inc. will post -2.73 earnings per share for the current fiscal year.
Several analysts recently issued reports on the stock. BidaskClub raised shares of Mirati Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. ValuEngine raised shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, November 16th. Cann reaffirmed a “buy” rating and issued a $18.00 price target on shares of Mirati Therapeutics in a report on Monday, January 8th. Oppenheimer set a $18.00 price target on shares of Mirati Therapeutics and gave the company a “buy” rating in a report on Monday, January 8th. Finally, HC Wainwright boosted their target price on shares of Mirati Therapeutics from $17.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, January 9th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $14.75.
Hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC bought a new stake in Mirati Therapeutics during the third quarter valued at $268,000. OxFORD Asset Management LLP bought a new stake in Mirati Therapeutics during the third quarter valued at $365,000. Susquehanna International Group LLP increased its stake in Mirati Therapeutics by 46.5% during the second quarter. Susquehanna International Group LLP now owns 50,509 shares of the biotechnology company’s stock valued at $184,000 after purchasing an additional 16,030 shares during the last quarter. PDT Partners LLC bought a new position in shares of Mirati Therapeutics during the second quarter worth about $200,000. Finally, Jane Street Group LLC bought a new position in shares of Mirati Therapeutics during the third quarter worth about $668,000. Hedge funds and other institutional investors own 64.68% of the company’s stock.
WARNING: This report was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/20/jamie-christensen-sells-10814-shares-of-mirati-therapeutics-inc-mrtx-stock.html.
Mirati Therapeutics Company Profile
Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The companys clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.
Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.